Please ensure Javascript is enabled for purposes of website accessibility

Toxin-fighting vaccine being tested

Integrated BioTherapeutics Inc., of Gaithersburg, a biotechnology company that is developing medical countermeasures for biodefense and emerging infectious diseases, announced the start of a Phase I clinical trial to test the safety and immune system responsiveness of STEBVAX, a new vaccine to fight a potent toxin called SEB.

SEB is a potential bioweapon that was once considered by the U.S. and USSR for military purposes, prior to an international ban on offensive biological and chemical weapons. The clinical trial is being conducted with an enrollment of 28 healthy adults at the University of Maryland, Baltimore’s Center for Vaccine Development.